Resources from the same session
4MO - Is it time for a new staging system for colon adenocarcinoma (CA)?
Presenter: N. Arvind Dasari
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
6MO - Evaluation of plasma assessed comprehensive genomic profiling before first-line treatment with FOLFIRI plus cetuximab in RAS/BRAFV600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial
Presenter: Giulia Martini
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Mini Oral session 1
Resources:
Webcast
5MO - Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145
Presenter: Giacomo Bregni
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
504MO - Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)
Presenter: Elisa Fontana
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 5MO and 504MO
Presenter: Takayuki Yoshino
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session 1
Resources:
Webcast
165MO - Early detection of HCC by routine blood based-AI
Presenter: Kin Nam Kwok
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
211MO - First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study
Presenter: Simron Singh
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 165MO and 211MO
Presenter: Lorenza Rimassa
Session: Mini Oral session 1
Resources:
Slides
Webcast